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Conclusions: CRD is an independent risk factor for throm-
boembolic events in patients with AF.
Perspective: Current practice guidelines consider the major
risk factors for thromboembolic events in patients with AF
to be age >75 years, hypertension, diabetes, heart failure,
and prior stroke. The results of this important study indicate
that CRD also should be considered a major risk factor for
stroke and taken into account when deciding whether a
patient with AF should be anticoagulated with warfarin.  
Summary written by: Fred Morady, MD
Congenital Heart Disease
Pulmonary Valve Replacement in Tetralogy of
Fallot: Impact on Survival and Ventricular
Tachycardia
Harrild DM, Berul CI, Cecchin F, et al.
Circulation 2009;119:445-451.
Study Design: What is the incidence of death and ventricular
tachycardia (VT) in patients with tetralogy of Fallot (TOF)
after pulmonary valve replacement (PVR)?
Methods: In this retrospective case-control study, 98 patients
with TOF who had undergone PVR were identified. Matched
control subjects with TOF, severe pulmonary regurgitation,
and right ventricular (RV) dilatation were identified for 77 of
these patients. Patients were matched by age (±2 years) and
QRS duration (±30 ms). Events were defined as VT, death, or
combined VT and/or death.
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Arrhythmias
Impact of Proteinuria and Glomerular Filtration
Rate on Risk of Thromboembolism in Atrial
Fibrillation. The Anticoagulation and Risk Factors
in Atrial Fibrillation (ATRIA) Study
Go AS, Fang MC, Udaltsova N, et al., on behalf of the ATRIA Study
Investigators.
Circulation 2009;119:1363-1369.
Study Design: Is chronic renal disease (CRD) a risk factor for
thromboembolic events in patients with atrial fibrillation (AF)?
Methods: This was a retrospective review of hospital records for
13,535 patients (mean age 72 years, 43% females) with non-
valvular AF. The estimated glomerular filtration rate (eGFR)
was calculated based on the serum creatinine concentration and
identification of proteinuria. Only thromboembolic events that
occurred in the absence of anticoagulation with warfarin were
analyzed.
Results: The eGFR was normal (≥60 ml/min/1.73 m2) in 57%
of patients, 45-59 ml/min/1.73 m2 in 18% of patients, <45
ml/min/1.73 m2 in 10%, and not available in 15%. During
33,165 person-years of follow-up, there were 676 thromboem-
bolic events. The rate of thromboembolism off warfarin was
lowest (1.6%/year) when the eGFR was normal, highest
(4.2%/year) when the eGFR was <45 ml/min/1.73 m2, and
intermediate (2.8%/year) when the eGFR was 45-59
ml/min/1.73 m2. When adjusted for other risk factors, an
eGFR <45 ml/min/1.73 m2 increased the risk of thromboem-
bolism by 39% and proteinuria increased the risk by 54%.
further research is required to optimally allocate organs for
pediatric heart transplantation.
Perspective: Some of the risk factors identified are also likely
to increase post-transplant morbidity and mortality. Any
organ allocation system should not only take into account a
patient’s risk on the waiting list, but also the prospect of a
successful long-term outcome to ensure that scarce organs
are used most appropriately. 
Summary written by: Timothy B. Cotts, MD 
General Cardiology
Risk of Adverse Outcomes Associated With
Concomitant Use of Clopidogrel and Proton Pump
Inhibitors Following Acute Coronary Syndrome
Ho PM, Maddox TM, Wang L, et al.
JAMA 2009;301:937-944.
Study Question: What are the outcomes of patients taking
clopidogrel with or without a proton pump inhibitor (PPI)
after hospitalization for acute coronary syndrome (ACS)?
Methods: This was a retrospective cohort study of 8,205
patients with ACS taking clopidogrel after discharge from 127
Veterans Affairs hospitals between October 1, 2003, and
January 31, 2006.The primary outcome was the combined
endpoint of all-cause mortality or rehospitalization for ACS
(myocardial infarction or unstable angina) following index
hospital discharge for ACS.
Results: AA total of 63.9% (n = 5,244) were prescribed PPI at
discharge, during follow-up, or both and 36.1% (n = 2,961)
were not prescribed PPI. Death or rehospitalization for ACS
occurred in 20.8% (n = 615) of patients taking clopidogrel
without PPI and 29.8% (n = 1,561) of patients taking clopi-
dogrel plus PPI. In multivariable analyses, use of clopidogrel
plus PPI was associated with an increased risk of death or
rehospitalization for ACS compared with clopidogrel without
PPI. Among patients taking clopidogrel after hospital dis-
charge and prescribed PPI at any point during follow-up (n =
5,244), periods of use of clopidogrel plus PPI (compared with
periods of use of clopidogrel without PPI) were associated
with a higher risk of death or rehospitalization for ACS. 
Conclusions: The concomitant use of clopidogrel and PPI
after hospital discharge for ACS was associated with an
increased risk of adverse outcomes compared to use of clopi-
dogrel without PPI.
Perspective: The results of this study may suggest that PPIs
should be used for patients only when clinically indicated and
not for routine prophylaxis. A recent expert consensus docu-
ment (J Am Coll Cardiol 2008;52:1502-17) calls for PPI
Results: There were no differences between the two groups in
age, QRS duration, type, or decade of initial repair or pres-
ence of VT prior to PVR, but there was more RV dilation in
the PVR group. No significant change in QRS duration was
seen in any group. In patients undergoing PVR, freedom
from death, VT, or both was 80% at 5 years and 40% at 10
years. In matched comparison, no differences were seen
between the PVR and control group in VT (p = 0.32), death
(p = 0.06), and combined VT and/or death (p = 0.21), with
trends favoring controls in all cases.
Conclusions: In a matched comparison, late PVR for sympto-
matic pulmonary regurgitation did not reduce the incidence
of VT or death.
Perspective: Significant limitations of this study include the
lack of randomization, and baseline differences in RV vol-
umes between the PVR and the control group, with patients
in the PVR group having larger RV volumes. Although
there were improved RV volumes in patients in this study,
there was no associated improvement in survival or rate of
arrhythmias. 
Summary written by: Timothy B. Cotts, MD 
Waiting List Mortality Among Children Listed for
Heart Transplantation in the United States
Almond CS, Thiagarajan RR, Piercey GE, et al.
Circulation 2009;119:717-727.
Study Design: What is the current wait list mortality for pedi-
atric heart transplant since revision of the pediatric heart
allocation system in 1999?
Methods: A multicenter cohort study was performed using the
US Scientific Registry of Transplant Recipients, examining
the 3,098 patients <18 years of age listed for a heart transplant
between 1999 and 2006. Exclusion criteria included repeat
heart transplant and multiple organ transplants.
Results: The median age was 2 years and the median weight
was 12.3 kg, with 1,874 listed as status 1A, of whom 30%
were on mechanical ventilation and 18% on extracorporeal
membrane oxygenation support (ECMO). Overall waiting list
mortality was 17% with 63% of patients receiving transplants,
8% recovering, and 12% remaining listed. Multivariate predic-
tors of waiting list mortality included ECMO (hazard ratio
[HR], 3.1; 95% confidence interval [CI], 2.4-3.9), ventilator
support (HR, 1.9; 95% CI, 1.6-2.4), listing status 1A (HR,
2.2; 95% CI, 1.7-2.7), congenital heart disease (HR, 2.2; 95%
CI, 1.8-2.6), dialysis support (HR, 1.9; 95% CI, 1.2-3.0), and
nonwhite race/ethnicity (HR, 1.7; 95% CI, 1.4-2.0).
Conclusions: Current waiting list mortality remains high, with
specific subgroups identifiable as high risk. The current
heart-allocation system identifies medical urgency poorly, and
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Predictors and Implications of Q-Waves in ST-
Elevation Acute Coronary Syndromes 
LaBounty T, Gurm HS, Goodman SG, et al., on behalf of the GRACE
Investigators.
Am J Med 2009;122:144-151. 
Study Question: What are the frequency, predictors, and
implications of Q-waves in the current era that includes pri-
mary percutaneous coronary interventions? 
Methods: There were 14,916 patients evaluated in a multicen-
ter observational study. They presented with ST-elevation
acute coronary syndromes between 1999 and 2006. Clinical
variables were compared between patients with versus without
presenting Q-waves. To assess the effect of Q-waves on 
6-month mortality, a stepwise logistic regression model 
was used.
Results: ST-elevation myocardial infarction occurred in
88.6% of patients. Q-waves were present on the initial elec-
trocardiogram in 3,929 patients and developed later in an
additional 3,085 patients. The incidence of Q-waves at
presentation or during hospitalization decreased from 61%
to 39% between 1999 and 2006 (linear trend p < 0.001).
Both presenting and subsequent Q-waves were associated
with greater likelihood of coronary occlusions and higher
cardiac marker elevations (p < 0.001). Multivariate analysis
showed that presenting Q-waves were associated with male
sex, increased age, diabetes, smoking, chronic aspirin and
other chronic cardiac medications, prior heart failure, and
prior coronary artery disease.
Conclusions: Q-waves in ST-elevation acute coronary syn-
dromes are decreasing, but are a major determinant of
in-hospital mortality, and targeted interventions should be
directed to these high-risk patients.
Perspective: The study suggests that Q-waves are associated
with larger infarcts and more occlusive lesions. Presenting Q-
waves are also associated with increased in-hospital mortality,
although they do not seem to impact 6-month mortality.
Given the prognostic importance of presenting Q-waves on
hospital survival, more aggressive initial and long-term man-
agement of these patients may be indicated.  
Summary written by: Debabrata Mukherjee, MD 
Factors Associated With Racial Differences in
Myocardial Infarction Outcomes
Spertus JA, Jones PG, Masoudi FA, Rumsfeld JS, Kumholz HM.
Ann Intern Med 2009;150:314-324. 
Study Question: What factors are associated with racial differ-
ences in myocardial infarction (MI) outcomes?
therapy for a majority of patients taking aspirin after MI,
including all patients 60 years and older, and may need to be
revisited by these societies.  
Summary written by: Debabrata Mukherjee, MD  
Clinical Presentation, Etiology, and Outcome of
Infective Endocarditis in the 21st Century: The
International Collaboration on Endocarditis–
Prospective Cohort Study
Murdoch DR, Corey GR, Hoen B, et al., on behalf of the International
Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS)
Investigators.
Arch Intern Med 2009;169:463-473.
Study Question: What is the contemporary worldwide presen-
tation, etiology, and outcome of infective endocarditis (IE)?
Methods: In a prospective study, the presentation, evaluation,
and outcomes were determined for 2,781 adults with definite
IE who were admitted to 58 hospitals in 25 countries
between June 1, 2000, and September 1, 2005. 
Results: The median age of the cohort was 57.9 years, and
72.1% had native valve IE. Most patients (77.0%) presented
early in the disease (<30 days) with few of the classic clinical
hallmarks of IE. Recent health care exposure was found in
one-quarter of patients. Staphylococcus aureus was the most
common pathogen (31.2%). The mitral (41.1%) and aortic
(37.6%) valves were most commonly infected. The following
complications were common: stroke (16.9%), embolization
other than stroke (22.6%), heart failure (32.3%), and intracar-
diac abscess (14.4%). Surgical therapy was common (48.2%),
and in-hospital mortality was high (17.7%). Prosthetic valve
involvement, increasing age, pulmonary edema, Staphylococcus
aureus infection, coagulase-negative staphylococcal infection,
mitral valve vegetation, and paravalvular complications were
associated with an increased risk of in-hospital death; whereas
viridans streptococcal infection and surgery were associated with
a decreased risk.
Conclusions: In the early 21st century, IE is more often an
acute disease, characterized by a high rate of Staphylococcus
aureus infection. Mortality remains relatively high.
Perspective: It will be interesting to use these data (gathered at
a time when antibiotic prophylaxis still was generally recom-
mended) as a baseline for comparison of IE prevalence and
nosocomial relationships in the next several years. If the overall
rates of infection do not increase and if nosocomial rates
remain in a relative minority, then the new recommendations
against antibiotic prophylaxis might be right after all. On the
other hand, why would I expose my patients to that risk?  
Summary written by: David S. Bach, MD 
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Methods: Subjects from the PREMIER registry were used
for the analysis of 1,849 subjects 18 years or older with a
documented MI. This study was restricted to black and
white patients admitted to the 10 centers, which enrolled 10
or more patients in each racial group. Telephone interviews
were conducted at 1, 6, and 12 months post-MI. Fifty-nine
patient, hospital, and treatment factors were compared and
classified into 11 domains and three phases of management.
Four outcomes were assessed including all-cause mortality
(at 2 years), rehospitalization (at 1 year), presence of angina
(at 1 year), and quality of life score (at 1 year).
Results: Unadjusted all-cause mortality was higher among
black patients compared to whites (19.9% vs. 9.3%, p <
0.001). Black patients also reported more anginal symptoms
(28.0% vs. 17.8%, p < 0.001) and a worse quality of life (mean
score 80.6 [standard deviation] 22.5 vs. 85.9 [17.2], p <
0.001). Rates of rehospitalization at 1 year were 45.4% for
blacks and 40.4% for whites (p = 0.13). After adjustment for
patient characteristics, a trend toward greater mortality, fewer
rehospitalizations, and higher likelihood of angina was
observed among the black compared with white patients.
Further adjustment for processes of care attenuated the
observed differences in mortality between racial groups.
Adjustment for treatments had minimal effect on any of these
associations.
Conclusions: Although black patients admitted with an MI
had worse outcomes, after controlling for patient factors and
site of care, these differences were no longer observed.
Strategies that focus on improving baseline cardiac risk and
hospital factors may do more than treatment-focused strate-
gies to attenuate racial differences in MI outcomes.
Perspective: These findings support the need for initiatives
that reduce differences between hospitals and monitor qual-
ity initiatives between sites of care. In addition, given the
relationship between socioeconomic status, comorbid condi-
tions (such as diabetes), and post-MI outcomes, prevention
efforts that reduce diabetes and reduce poverty will signifi-
cantly improve racial disparities in cardiac health.  
Summary written by: Elizabeth A. Jackson, MD  
Interventional Cardiology
A Bioabsorbable Everolimus-Eluting Coronary Stent
System (ABSORB): 2-Year Outcomes and Results
From Multiple Imaging Methods
Serruys PW, Ormiston JA, Onuma Y, et al.
Lancet 2009;373:897-910.
Study Question: How safe and feasible is the bioabsorbable
everolimus-eluting stent (BVS)?
Methods: This was a feasibility trial designed to provide pre-
liminary observations and generate hypotheses for future
studies. A total of 30 patients with a single de-novo coronary
artery lesion were followed up for 2 years clinically and with
multiple imaging methods. Clinical data were obtained from
29 of 30 patients. 
Results: At 2 years, the device was safe with no cardiac deaths,
ischemia-driven target lesion revascularizations, or stent
thromboses recorded, and only one myocardial infarction
(non-Q wave). Eighteen-month multislice CT (assessed in 25
patients) showed a mean diameter stenosis of 19% (standard
deviation [SD] 9). At 2-year angiography, the in-stent late
loss of 0.48 mm (SD 0.28) and the diameter stenosis of 27%
(11) did not differ from the findings at 6 months. At 2 years,
34.5% of strut locations presented no discernible features by
OCT, confirming decreases in echogenicity and in radiofre-
quency backscattering; the remaining apparent struts were fully
apposed. Additionally, vasomotion occurred at the stented site
and adjacent coronary artery in response to vasoactive agents.
Conclusions: At 2 years after implantation, the stent was
bioabsorbed, and had vasomotion restored, restenosis pre-
vented, and was clinically safe.
Perspective: Note that the lesions treated in this study represent
only the simplest in current practice, and the radial strength of
this stent will require further testing in more complex lesions.
These preliminary findings need to be confirmed in larger
prospective studies, but bioabsorbable stents may be unique for
treatment of flow-limiting plaque by eliminating the obstruc-
tion and restoring vascular integrity.  
Summary written by: Debabrata Mukherjee, MD 
Percutaneous Coronary Interventions for Non-
Acute Coronary Artery Disease: A Quantitative
20-Year Synopsis and a Network Meta-Analysis
Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM.
Lancet 2009;373:911-918.
Study Question: How has evolution in technology impacted
the long-term risk of death or myocardial infarction (MI) in
patients undergoing percutaneous coronary intervention
(PCI) for stable disease?
Methods: This systematic overview of randomized trials com-
pared at least two of four interventions; percutaneous
coronary transluminal angioplasty (PTCA), bare-metal
stents (BMS), drug-eluting stents (DES), and medical ther-
apy in patients with nonacute coronary artery disease. The
endpoints evaluated were death, MI, coronary artery bypass
grafting, target lesion or vessel revascularization, and any
revascularization. Random effects meta-analyses were used
for direct comparisons, and network meta-analysis was used
to provide indirect evidence.
JACC Vol. 53, No. 18, 2009
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Conclusions: PCI for occluded arteries was associated with a
minor advantage in cardiac physical function at 4 months,
but not subsequently. Medical therapy was significantly less
expensive than routine PCI and was associated with margin-
ally longer quality-adjusted survival.
Perspective: The key finding of the OAT trial was that PCI
for occlusion of the infarct-related artery 3-28 days after MI
did not reduce the occurrence of death, reinfarction, or heart
failure, with a trend toward excess reinfarction during 4
years of follow-up with invasive therapy. Since PCI in this
scenario is not clinically beneficial and is considered inap-
propriate, the cost-effectiveness of the strategy is clinically
irrelevant and purely an academic exercise.  
Summary written by: Hitinder S. Gurm, MBBS  
Prasugrel Compared With Clopidogrel in Patients
Undergoing Percutaneous Coronary Intervention for
ST-Elevation Myocardial Infarction (TRITON-TIMI
38): Double-Blind, Randomised Controlled Trial
Montalescot G, Wiviott SD, Braunwald E, et al., on behalf of the 
TRITON-TIMI 38 Investigators.
Lancet 2009;373:723-731.
Study Question: What is the benefit of using prasugrel (versus
clopidogrel) in patients undergoing percutaneous coronary
intervention (PCI) for ST-elevation myocardial infarction
(STEMI)?
Methods: This was a prespecified analysis of the TRITON-
TIMI 38 study; 3,534 patients presenting with STEMI
were randomly assigned to either prasugrel (60 mg loading,
10 mg maintenance [n = 1,769]) or clopidogrel (300 mg
loading, 75 mg maintenance, n = 1,765). The patients were
divided into two categories, those enrolled within 12 hours
of onset of symptoms (primary PCI, n = 2,438); and those
enrolled between 12 hours and 14 days after symptom onset
(secondary PCI). Follow-up was to 15 months.
Results: PCI was performed in 3,425 (97%) patients and stents
were used in 3,257 (92%). Bare-metal stents were used in 59%
and drug-eluting stents were used in 33% of the total cohort.
The primary endpoint was significantly reduced with prasu-
grel at 30 days (hazard ratio [HR], 0.68; 95% confidence
interval [CI], 0.54-0.87; p = 0.0017), and 15 months (HR,
0.79; 95% CI, 0.65-0.97; p = 0.0221). The benefits of prasu-
grel were more marked in patients undergoing secondary PCI
compared with those undergoing primary PCI. There was no
difference between clopidogrel and prasugrel with respect to
the risk of thrombolysis in myocardial infarction (TIMI)
major bleeding unrelated to coronary artery bypass graft
(CABG) surgery at 30 days (p = 0.34) and 15 months (p =
0.65), although TIMI major bleeding after CABG was signif-
icantly increased with prasugrel (18.8% vs. 2.7%, p = 0.0033). 
Results: There were 61 trials (enrolling 25,388 patients) that
investigated four of six possible comparisons between the
four interventions. In all comparisons, cumulative advance-
ments in PCI did not produce detectable improvements in
deaths or MI. The risk ratio (RR) for indirect comparisons
between DES and medical therapy was 0.96 (95% confi-
dence interval [CI], 0.60-1.52) for death and 1.15
(0.73-1.82) for MI. There was significant improvement in
target lesion or vessel revascularization with BMS compared
with PTCA (RR, 0.68; 95% CI, 0.60-0.77) and with DES
compared with BMS (RR, 0.44; 95% CI, 0.35-0.56).
Conclusions: Cumulative advances in PCI have not translated
into an improvement in survival or a reduction in MI.
Perspective: No trial has demonstrated a reduction in death or
MI with PCI, so these results are no surprise. The fact that
the risk of restenosis decreased as we moved from PTCA to
BMS to DES is no revelation either. This study provides a
comprehensive synthesis of the totality of evidence in the field
and is strong endorsement for a medical therapy first approach
to patients with stable coronary artery disease.  
Summary written by: Hitinder S. Gurm, MBBS 
Quality of Life After Late Invasive Therapy for
Occluded Arteries
Mark DB, Pan W, Clapp-Channing NE, et al., on behalf of the 
Occluded Artery Trial Investigators.
N Engl J Med 2009;360:774-783.
Study Question: What are the quality-of-life and economic
outcomes associated with late opening of an infarct-related
artery after myocardial infarction (MI)?
Methods: The authors analyzed the quality-of-life and eco-
nomic outcomes associated with percutaneous coronary
intervention (PCI) in the OAT trial. Quality of life was
assessed in 951 patients via a battery of teststhat included
two principal outcome measures. Structured quality-of-life
interviews were performed at baseline and at 4, 12, and 24
months. Costs of treatment were assessed for 458 patients
enrolled in the United States, and 2-year cost-effectiveness
was estimated.
Results: There was a marginal decrease in the Duke Activity
Status Index (DASI) score at 4 months in the medical therapy
group, as compared with the PCI group (difference of 3.4
points, p = 0.007). These differences were attenuated further
at 1 and 2 years. There were no significant differences in psy-
chological well-being between patients randomized to each
arm. For the 469 patients in the United States, cumulative 2-
year costs were approximately $7,000 higher in the PCI group
(p < 0.001), and the quality-adjusted survival was marginally
longer in the medical therapy group. 
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Conclusions: In patients with STEMI undergoing PCI, pra-
sugrel is more effective than clopidogrel for prevention of
ischemic events.
Perspective: Prasugrel has been recently approved in Europe
and is likely to see widespread use in patients with STEMI
and non-STEMI in the near future. A major concern with
prasugrel is increased bleeding, which did not appear to be a
big problem in this substudy (except in those undergoing
CABG).  Further studies are needed to define the optimal
patient subgroups with STEMI who would benefit from use
of prasugrel (in lieu of clopidogrel).  
Summary written by: Hitinder S. Gurm, MBBS  
Noninvasive Cardiology
Hand-Carried Ultrasound Performed by Hospitalists:
Does It Improve the Cardiac Physical Examination?
Martin LD, Howell EE, Ziegelstein RC, et al.
Am J Med 2009;122:35-41.
Study Question: What is the incremental benefit of hand-car-
ried ultrasound (HCU) compared to the standard physical
exam (PE) as rendered by hospitalists for the diagnosis of
cardiovascular disease?
Methods: Physical examination followed by HCU was per-
formed by 10 hospitalists in 354 general medical inpatients.
Each hospitalist underwent relatively limited training in the
use of HCU. PEs were specifically targeted to detection of
pericardial effusion (PEF), aortic and mitral regurgitation
(AR, MR), aortic stenosis (AS), cardiomegaly (CM), and
estimated left ventricular function (LVF). Hospitalist PEs and
HCUs were then compared to results of formal echocardiog-
raphy.
Results: AR was present in 84 patients and detected by PE
in 7% and by HCU in 35%; AR was absent in 206 patients,
86% of whom were correctly identified by PE versus 59%
by HCU (both p = 0.001). AS was present in 50 patients
and detected by PE in 20% and by HCU in 34%, and was
absent in 286 and correctly identified in 84% by PE and
79% by HCU (p = NS). MR was present in 176 patients
and identified on PE in 15% and by HCU in 35%. MR
was absent in 114 and correctly classified in 79% by PE and
54% by HCU (both p = 0.001). PE was present in 67
patients and detected by PE in only 3% and by HCU in
60%, and was absent in 269 and correctly identified in 61%
on PE and 84% by HCU (both p = 0.001). LVF precisely
matched the results of formal echocardiography in 12% and
32% by PE and HCU in those with abnormal function and
in 64% and 73% in those with normal function.
Conclusions: Addition to HCU to physical exam increases the
accuracy of a hospitalist for assessment of LVF, cardiomegaly,
and PEF, but not for assessment of valvular disease.
Perspective: This study is somewhat surprising in that the
incremental diagnostic accuracy of HCU appears less than in
a number of previous studies. A major limitation of HCU in
this study was that it led to an increase in diagnosis of valvu-
lar insufficiency in patients documented to be free of such on
formal echocardiography. The degree to which this limita-
tion is related to the population being evaluated versus the
specific equipment utilized is conjectural.  
Summary written by: William F. Armstrong, MD 
Prevention/Vascular
Comparison of Weight-Loss Diets With Different
Compositions of Fat, Protein, and Carbohydrates
Sacks FM, Bray GA, Carey VJ, et al.
N Engl J Med 2009;360:859-873.
Study Question: Is there any difference in weight loss from
diets that emphasize relative restriction of fat, carbohydrates,
or protein with follow-up that extends beyond 1 year?
Methods: A total of 811 overweight adults ages 30-70 years
with a body mass index (BMI) from 25 to 40 kg/m2 were ran-
domized to one of four diets; the targeted percentages of
energy derived from fat, protein, and carbohydrates in the four
diets were 20, 15, and 65%; 20, 25, and 55%; 40, 15, and 45%;
and 40, 25, and 35%. The diets consisted of similar foods and
met guidelines for cardiovascular health. The participants were
offered group and individual instructional sessions for 2 years.
Results: Mean age was about 50 years, >60% were women,
about 80% were white and 15% black, 32% had the metabolic
syndrome, and >70% of the 645 patients who completed the
study had a BMI >30 kg/m2. At 6 months, participants
assigned to each diet had lost an average of 6 kg, which repre-
sented 7% of their initial weight. They began to regain weight
after 12 months. By 2 years, weight loss remained similar in
those who were assigned to a diet with 15% protein and those
with 25% protein (3.0 and 3.6 kg, respectively); in those
assigned to a diet with 20% fat and those with 40% fat (3.3 kg
for both groups); and in those assigned to a diet with 65% car-
bohydrates and those with 35% carbohydrates (2.9 and 3.4 kg,
respectively) (p > 0.20 for all comparisons). Among the 80% of
participants who completed the trial, the average weight loss
was 4 kg. Attendance at group sessions was strongly associated
with weight loss (0.2 kg per session attended). The diets
improved lipid-related risk factors and fasting insulin levels.
Conclusions: Reduced-calorie diets result in clinically mean-
ingful weight loss regardless of which macronutrients they
emphasize.
JACC Vol. 53, No. 18, 2009
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Perspective: That only 15% of subjects lost at least 10% of their
body weight is surprising, and provides a reference for
expected results from office-based practice and nutritionists.
The best diet is that with which an individual patient can be
compliant, and includes the opportunity to eat whatever food
groups that are preferred while reducing total caloric intake.  
Summary written by: Melvyn Rubenfire, MD 
Metabolic Syndrome and Salt Sensitivity of Blood
Pressure in Non-Diabetic People in China: A
Dietary Intervention Study
Chen J, Gu D, Huang J, et al., on behalf of the GenSalt Collaborative
Research Group.
Lancet 2009;373:829-835.
Study Question: Is there an association between metabolic syn-
drome and salt sensitivity of blood pressure?
Methods: A total of 1,906 Chinese participants without dia-
betes, ages 16 years or more, received a low-sodium diet
(51.3 mmol per day) for 7 days, followed by a high-sodium
diet (307.8 mmol per day) for an additional 7 days. Blood
pressure was measured at baseline and on days 2, 5, 6, and 7
of each intervention. Metabolic syndrome was defined as the
presence of three or more of: abdominal obesity, raised
blood pressure, high triglyceride concentration, low high-
density lipoprotein cholesterol, or high glucose. High salt
sensitivity was defined as a decrease in mean arterial blood
pressure of more than 5 mm Hg during low-sodium or an
increase of more than 5 mm Hg during high-sodium inter-
vention.
Results: Mean age was about 39 years and 50% were men.
Of the 1,881 participants with information regarding meta-
bolic syndrome, 283 had metabolic syndrome; 1,853
participants completed the low-sodium diet and 1,845 com-
pleted the high-sodium diet. Multivariable-adjusted mean
changes in blood pressure were significantly greater in par-
ticipants with metabolic syndrome than in those without on
both low-sodium and high-sodium diets (p < 0.0001 for all
comparisons). Risk of salt sensitivity rose with increasing
numbers of risk factors for metabolic syndrome. Compared
with those with no risk factors, participants with four or
five had a 3.54-fold increased odds of high salt-sensitivity
during the low-sodium and a 3.13-fold increased odds of
high salt-sensitivity during the high-sodium intervention.
The multivariable-adjusted mean responses in participants
with no metabolic risk factors versus those with four/five
during the low-sodium intervention were –4.30 mm Hg
versus –9.39 mm Hg for systolic and –1.86 mm Hg versus
–6.06 mm Hg for diastolic blood pressure, respectively
Conclusions: The metabolic syndrome enhances blood pres-
sure response to sodium intake. Reduction in sodium intake
could be an especially important component in reducing
blood pressure in patients with multiple risk factors for
metabolic syndrome.
Perspective: Clinical studies have suggested that insulin resist-
ance might lead to sodium retention and extracellular fluid
volume expansion, thereby increasing blood pressure
responses to sodium intake. In this study, waist circumference
was significantly associated with blood pressure responses to
dietary sodium intake, implying that abdominal obesity might
be an especially important factor in determining an individ-
ual’s blood pressure response to variation in sodium intake.  
Summary written by: Melvyn Rubenfire, MD 
ACAT Inhibition and Progression of Carotid
Atherosclerosis in Patients With Familial
Hypercholesterolemia: The CAPTIVATE
Randomized Trial
Meuwese MC, de Groot E, Duivenvoorden R, et al.
JAMA 2009;301:1131-1139.
Study Question: Does inhibition of the ACAT, an intracellu-
lar enzyme involved in cholesterol accumulation, with
pactimibe, reduce progression of carotid atherosclerosis?
Methods: CAPTIVATE was a prospective, randomized, strati-
fied, double-blind, placebo-controlled study of 892 patients
heterozygous for familial hypercholesterolemia conducted at
40 lipid clinics in the United States, Canada, Europe, South
Africa, and Israel between Feb. 1, 2004, and Dec. 31, 2005.
Results: After 6 months of treatment with pactimibe, low-
density lipoprotein cholesterol increased by 7.3% compared
with 1.4% in the placebo group (p = 0.001). The carotid
ultrasonographic scans of the 716 patients, who had at least
two scans obtained at least 40 weeks apart, were analyzed.
Maximum CIMT measurements did not show a pactimibe
treatment effect; however, the mean CIMT measurement
revealed an increase of 0.014 mm in patients administered
pactimibe versus placebo. Major cardiovascular events (car-
diovascular death, myocardial infarction, and stroke)
occurred more often in patients administered pactimibe ver-
sus placebo.
Conclusions: In patients with familial hypercholesterolemia,
pactimibe had no effect on atherosclerosis as assessed by
changes in maximum CIMT compared with placebo, but
was associated with an increase in mean CIMT as well as
increased incidence of major cardiovascular events.
Perspective: The current study indicates that ACAT inhibi-
tion may actually increase atherosclerosis in the carotid
arteries and that this may increase clinical events. Taken
together with other clinical trials, inhibition of ACAT does
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not appear to be a useful strategy for reduction of cardiovas-
cular risk, and may cause harm.  
Summary written by: Daniel T. Eitzman, MD 
Aspirin for the Prevention of Cardiovascular
Disease: U.S. Preventive Services Task Force
Recommendation Statement
U.S. Preventive Services Task Force.
Ann Intern Med 2009;150:396-404.
Perspective: The following are 10 points to remember about
aspirin for the prevention of cardiovascular disease:  
1. The lifetime risk of cardiovascular events in adults older
than 40 years is two in three for men and more than one in
two for women. 
2. These U.S. Preventive Services Task Force recommenda-
tions are for men and women without known coronary
disease or stroke, and based on a 32% reduction in risk of
myocardial infarction (MI) in men and a 17% reduction in
stroke in women with regular aspirin use. 
3. Estimated gastrointestinal (GI) bleeds per 1,000 men
would be 8 at 45-59 years, 24 at 60-69 years, and 36 at 70-
79 years; and for 1,000 women: 4, 12, and 18, respectively. 
4. Encourage men ages 45-79 years to use aspirin when the
potential benefit of a reduction in MIs outweighs the poten-
tial harm of an increase in GI hemorrhage (Level A
recommendation). 
5. The value of aspirin for reducing MI would exceed risk of
GI bleeding if 10-year risk is ≥4% in men 45-59 years, ≥9%
in men 60-69 years, and ≥12% in men 70-79 years. 
6. Encourage women ages 55-79 years to use aspirin when
the potential benefit of a reduction in ischemic strokes out-
weighs the potential harm of an increase in GI hemorrhage
(Level A recommendation). 
7. The value of aspirin for reducing strokes in women would
exceed risk of bleeding if the 10-year risk is ≥3% for women
55-59 years, ≥8% for women 60-69 years, and ≥11% for
women 70-79 years. 
8. A dose of about 75 mg/d seems as effective as higher doses. 
9. Evidence is insufficient to assess the balance of benefits
and harms of aspirin for cardiovascular disease prevention in
men and women ages 80 years or older. Do not encourage
aspirin use for cardiovascular disease prevention in women
younger than 55 years and in men younger than 45 years
(Level D recommendation). 
10. Clinicians and policymakers should understand the evi-
dence, but individualize decision making to the specific
patient or situation.
Summary written by: Melvyn Rubenfire, MD
Coffee Consumption and Risk of Stroke in Women
Lopez-Garcia E, Rodriguez-Artalejo F, Rexrode KM, Logroscino G, 
Hu FB, van Dam RM.
Circulation 2009;119:1116-1123.
Study Question: Is coffee consumption associated with stroke
among women?
Methods: Data from the Nurses’ Health Study were used for
the analysis. Women with no prior history of stroke, coronary
heart disease, diabetes, or cancer at baseline were included.
Coffee consumption was assessed through self-report begin-
ning in 1980 and every 2-4 years until 2004. Outcomes of
interest included total stroke, hemorrhagic, ischemic, and
undetermined stroke subcategories.
Results: A total of 83,076 women were included in the
analysis; 2,280 experienced a stroke during the follow-up
period including 426 hemorrhagic and 1,224 ischemic
strokes, and 630 strokes having an undetermined etiology.
After adjustment for multiple factors, no increased risk was
observed between coffee consumption and risk of stroke
from <1 cup per month to 4 per week (0.98; 95% confi-
dence interval [CI], 0.84-1.15), 5-7 per week (0.88; 95%
CI, 0.77-1.02), 2-3 per day (0.81; 95% CI, 0.70-0.95), to
≥4 per day (0.80; 95% CI, 0.64-0.98) compared with non-
coffee drinkers. Increasing intake of coffee appeared to be
mildly protective for stroke. After further adjustment for
high blood pressure, elevated cholesterol, and type 2 dia-
betes, this inverse relationship remained statistically
significant. The protective association also appeared more
pronounced among past and never smokers.
Conclusions: Consumption of coffee was not associated with
increased risk of stroke among apparently healthy women.
Perspective: These findings suggest no increased risk for
stroke among women who consume coffee or other caf-
feinated beverages. In fact, a small protective benefit was
observed. Given this finding, stroke prevention should con-
tinue to focus on known risk factors such as smoking and
hypertension.  
Summary written by: Elizabeth A. Jackson, MD
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